Engineers Gate Manager LP Makes New $1.12 Million Investment in Supernus Pharmaceuticals, Inc. $SUPN

Key Points

• Engineers Gate Manager LP purchased 24,070 shares of Supernus Pharmaceuticals worth approximately $1.12 million in the second quarter. BlackRock and several other institutional investors also initiated or increased positions.
• Supernus reported quarterly revenue of $219.1 million, up 32.4% year over year and above analyst expectations, but posted an EPS loss of $1.01 versus the $0.42 consensus estimate.
• SUPN shares opened at $42.00, near their 12-month low of $40.51. Analyst sentiment is mixed, with a consensus “Hold” rating and an average price target of $62.83.

Engineers Gate Manager LP purchased a new stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 24,070 shares of the specialty pharmaceutical company's stock, valued at approximately $1,119,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in SUPN. BlackRock Inc. purchased a new stake in shares of Supernus Pharmaceuticals during the second quarter valued at $434,871,000. Geode Capital Management LLC increased its position in shares of Supernus Pharmaceuticals by 4.5% in the 4th quarter. Geode Capital Management LLC now owns 1,472,899 shares of the specialty pharmaceutical company's stock valued at $73,215,000 after acquiring an additional 62,875 shares during the period. Bank of America Corp DE raised its stake in Supernus Pharmaceuticals by 37.2% in the 1st quarter. Bank of America Corp DE now owns 714,226 shares of the specialty pharmaceutical company's stock worth $36,918,000 after acquiring an additional 193,479 shares during the last quarter. Ashford Capital Management Inc. raised its stake in Supernus Pharmaceuticals by 5.4% in the 1st quarter. Ashford Capital Management Inc. now owns 645,381 shares of the specialty pharmaceutical company's stock worth $33,360,000 after acquiring an additional 32,843 shares during the last quarter. Finally, Sofinnova Investments Inc. lifted its position in Supernus Pharmaceuticals by 46.7% during the 4th quarter. Sofinnova Investments Inc. now owns 553,095 shares of the specialty pharmaceutical company's stock worth $27,489,000 after acquiring an additional 176,029 shares during the period.

Supernus Pharmaceuticals Price Performance

Shares of SUPN stock opened at $42.00 on Friday. The firm's 50-day moving average is $45.51 and its two-hundred day moving average is $47.68. Supernus Pharmaceuticals, Inc. has a 12 month low of $40.51 and a 12 month high of $59.68. The company has a market capitalization of $2.45 billion, a PE ratio of -21.87, a price-to-earnings-growth ratio of 0.79 and a beta of 0.56.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last posted its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of $0.42 by ($1.43). Supernus Pharmaceuticals had a negative net margin of 13.23% and a positive return on equity of 11.13%. The firm had revenue of $219.06 million during the quarter, compared to analysts' expectations of $205.31 million. During the same period last year, the company earned $0.40 EPS. The business's quarterly revenue was up 32.4% on a year-over-year basis. Sell-side analysts forecast that Supernus Pharmaceuticals, Inc. will post 1.97 EPS for the current year.

Analyst Ratings Changes

Several research analysts have recently issued reports on SUPN shares. Zacks Research cut Supernus Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Friday, September 4th. Wall Street Zen downgraded Supernus Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Saturday, August 8th. Weiss Ratings reiterated a "sell (d+)" rating on shares of Supernus Pharmaceuticals in a research report on Wednesday, June 24th. Finally, Cantor Fitzgerald increased their price target on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an "overweight" rating in a report on Thursday, July 9th. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $62.83.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing treatments for central nervous system (CNS) disorders. The company's portfolio addresses conditions including epilepsy, migraine and attention-deficit/hyperactivity disorder (ADHD), with an emphasis on extended-release and other drug-delivery technologies.

Supernus markets Oxtellar XR (oxcarbazepine extended-release) for the treatment of partial-onset seizures and Trokendi XR (topiramate extended-release) for certain epilepsy indications and the prevention of migraine headaches.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.